Primitive neuro-ectodermal tumours (PNET) are neuroepithelial neoplasms arising from the germinal matrix of the primitive neural tube. Primitive neuro-ectodermal tumours are predominately a tumour of childhood, accounting for about 20% of primary central nervous system (CNS) malignancies in children 1 . Typically PNETs occur in the posterior fossa, but supratentorial PNETs in children still account for about 2.8% of all primary tumours of childhood and adolescence 2 . Much is known about the management of PNETs in children. In adults, on the other hand, supratentorial PNETs are exceedingly rare, with only a handful of cases reported in the current literature. Thus, optimal medical management of supratentorial PNETs in adults remains unclear. Chemotherapy options that have been utilized in previous reports include conventional agents such as vincristine, cisplatinum, cyclophosphamide, procarbazine, and CCNU 2, 3 , in addition to recent reports of successful treatment with temozolomide 1, 4 . Here, we present the case of a patient with a supratentorial PNET diagnosed in adulthood, with tumour recurrence on carboplatin and etoposide, which responded to subsequent treatment with temozolomide.
CASE REPORT
A 42-year-old man presented to the ED with a few weeks history of headache, confusion, nausea, vomiting, and progressive left-sided hemiparesis. An magnetic resonance image (MRI)-head showed a 6.3 x 5.2 x 5.0 cm partially cystic enhancing mass in the right basal ganglia, with mild surrounding edema and mass effect causing a midline shift of seven mm and right lateral ventricle effacement.
He subsequently underwent craniotomy and gross total excision of the tumour. Clinically, he improved significantly after the surgery and had minimal residual deficits.
Pathology showed a highly cellular tumour composed of poorly differentiated small round blue cells forming pseudorosettes around vessels. The nuclei were pleomorphic with numerous mitoses and apoptotic bodies, with no necrosis (Figure 1 ). Immunohistochemistry was positive for synaptophysin and negative for CD45, LMWK, HMWK and GFAP, NF, SMI31 and NeuN. These results were deemed consistent with PNET, but a metastatic neuro-endocrine tumour could not be excluded.
He went on to have further imaging, including a computed tompogram (CT) of the chest, abdomen, and pelvis, which did not reveal any findings suggestive of a primary malignancy. Routine staging investigations for radiotherapy included further imaging of his spine and cerebrospinal fluid (CSF) studies to assess for drop metastases. The MRI-spine showed some evidence of degenerative changes in the cervical and thoracic spines, but no evidence of leptomeningeal enhancement. However, in the CSF, there was evidence of malignant cells with two atypical groups of cells with a moderate amount of cytoplasm and irregular nuclei present. He subsequently underwent external beam and cranio-spinal radiation therapy with minimal complications. A follow-up MRI-head showed no evidence of recurrent disease. He was monitored with serial imaging studies.
Nine months after completing radiotherapy, an MRI-head showed a new area of nodular enhancement in the resection cavity. A thallium scan confirmed avid uptake in this area, which was suggestive of recurrent disease, as opposed to radiation necrosis. He was thus started on adjuvant carboplatin/etoposide chemotherapy (carboplatin once/month, continuous two-week cycles of etoposide). He tolerated this regimen well, and had no significant clinical or hematological side effects. Unfortunately, after completing three cycles of this regimen, a repeat MRI-head showed evidence of tumour progression, with an increase in size of the enhancing mass from 2.2 x 1.9 cm to 3.5 x 2.9 cm (Figure 2A ).
In the absence of any distinct guidelines regarding treatment of this rare tumour, his chemotherapy regimen was then switched to temozolomide at 300 mg per day (150 mg/m 2 ) in conventional 5/28 day cycles. He tolerated the medication quite well with no significant clinical or hematological side effects. He was seen in repeat consultation by the radiation oncologist, who determined that he was not a candidate for repeat radiotherapy at that time, as he had recently received a course of radical radiotherapy. He was also seen in follow-up by the neurosurgeon involved in his care, and surgery was to be considered only as a last-resort option, if he did not respond to medical management.
An MRI-head obtained after the patient completed two cycles of temozolomide showed clear evidence of a response ( Figure  2B ). The enhancing mass had diminished significantly in size to 1 cm x 1 cm, with only a small amount of residual enhancing tissue within the right frontal/temporal lobe. After completing four cycles of temozolomide, the response was sustained with no radiographic evidence of change in comparison to the previous scan ( Figure 2C ). The patient remained clinically well with no significant side effects from the medication. Given his positive response to temozolomide, the activity of the DNA repair enzyme MGMT (O6-methylguanine-DNA methyltransferase) was assessed in our patient's pathological specimen by assessing for methylation of the promoter region, which functionally acts to silence the gene. This was carried out by MSP (methylation specific polymerase chain reaction [PCR]) following bisulfate treatment of DNA extracted from formalin paraffin embedded tissue. Interestingly, this patient's MGMT promoter was methylated, which is in keeping with his response to temozolomide (Figure 3) .
Unfortunately, after six cycles of temozolomide chemotherapy, there was evidence of recurrence on MRI ( Figure 2D ). At this point, his chemotherapy was changed to daily temozolomide at 100 mg daily (50 mg/m 2 ) as "rescue" therapy, with no improvement at two months. He subsequently underwent further tumour resection, and was started on CCNU chemotherapy at 200 mg, given in six week cycles. After one cycle of CCNU, there was stabilization of his tumour. However, after four cycles of treatment, he had clear evidence of tumour recurrence with significant clinical deterioration, and died within a few months.
DISCUSSION
Supratentorial PNET in adults is an uncommon entity. A previous study reports only 57 cases of supratentorial PNET in adults in the existing literature 2 . Due to its low incidence, to date, the optimal medical management of this tumour remains unknown.
Current management initially consists of total resection, if possible, followed by radiotherapy. Due to the propensity of PNET to disseminate in CSF, radiation of the entire neuroaxis is usually recommended 2 . The prognosis of PNET has improved significantly with radiotherapy, and long-term survival in adults is reported to be 50-60% at five years 5 . Adjuvant chemotherapy is utilized in some centres, but the available data is unclear about its role 4 . Agents that have been used in previous reports include CCNU, vincristine, cisplatinum, procarbazine, etoposide, cyclophosphamide, and carboplatin 4 . There have been variable response rates reported with these agents.
Temozolomide is a newer alkylating chemotherapeutic agent used in the treatment of glioblastoma multiforme and anaplastic astrocytoma. This agent is generally well-tolerated, with the main major side effects being nausea and myelosuppression.
In the existing literature, temozolomide use in the context of adult PNET recurrence has only been reported in a handful of previous cases (Table) . One case described temozolomide use in recurrence of a previously diagnosed childhood PNET 1 . The second case is that of recurrent adult supratentorial PNET 4 . Both cases reported showed good responses with the use of temozolomide. Two other cases describe initial responses followed by subsequent relapses of adults with recurrent PNET treated with temozolomide chemotherapy 6, 7 . Finally, two previous case series of adult PNET patients mention three cases that demonstrated a response with temozolomide 8, 9 . Our case was that of an aggressive supratentorial PNET that failed chemotherapy with the more conventional agents: carboplatin and etoposide. With temozolomide, however, the tumour showed a striking radiographic response that was durable 2 patientsdemographics n/a n/a n/a for six months. Our patient tolerated this medication well with no significant side effects. Our patient's pathological specimen had a methylated MGMT promoter, which functionally acts to silence the DNA repair gene. The MGMT promoter methylation has been shown to predict a beneficial response to temozolomide in patients with glioblastoma multiforme (GBM) 10 , and may be predictive of response in other tumors as well. A recent report describes an aggressive pituitary tumor that responded to temozolomide chemotherapy. On immunohistochemistry, this tumor showed lack of MGMT staining, while another pituitary tumor unresponsive to temozolomide showed high expression of MGMT 11 . In the existing literature, to our knowledge, MGMT methylation status has never been reported in the context of adult supratentorial PNETs treated with temozolomide. Our case is unique in that we have documented a clear clinical response of an adult-onset supratentorial PNET to temozolomide which was durable for six months, together with evidence of a methylated MGMT promoter region, which is in keeping with the literature for MGMT methylation in GBM.
This case adds to the small body of literature regarding the medical management of adult supratentorial PNET. Clearly, further investigations are needed prior to establishing guidelines regarding optimal medical management of this rare tumour. Future studies looking at MGMT methylation status in PNET in relation to temozolomide responsiveness may be helpful to further explore the utility of temozolomide in this tumour. In the absence of established guidelines, however, given the tolerability and ease of administration of temozolomide, this agent should be considered as an option for chemotherapy in patients with aggressive PNET. Furthermore, our case illustrates that the methylation status of MGMT promoter may be useful in predicting a response to temozolomide in these patients.
